SEC Compliance Featuring Products From Tauriga Sciences, Inc. at B. Riley & Co. Conference
Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced today that its products will be featured at the SEC Compliance sponsor booth at this week’s 16thAnnual B. Riley & Co. Investor Conference on May 12th-14th at The Loews Hollywood Hotel in Los Angeles, California. B. Riley & Co.’s investment conference highlights over 250 publicly-traded companies and dozens of privately-held firms showcasing their stories to an expected audience of institutional investors, corporate clients, and high-net worth individuals.
SEC Compliance, a leading filing agency registered with the Securities and Exchange Commission providing a full-service turnkey solution for regulatory requirements, is a sponsor of the conference and will be featuring TopiCanna, Tauriga’s proprietary topical medicinal cannabis cream, with the tagline, “Make it painless with SEC Compliance and Tauriga Sciences.” SEC Compliance had previously featured Tauriga’s natural wellness products at their sponsor booth at the ROTH Capital Conference in March, and both companies were pleased with the level of interest generated in SEC Compliance’s well-priced service offerings and Tauriga’s innovative new product line.
Medicinal properties of cannabis are of great interest to the general and investing public, and many who have used topical cannabis creams have reported decreased musculoskeletal pain without psychoactive effects. Product information, labels and testimonials are available on Tauriga’s e-commerce website, www.taurigastore.com.
David McGuire, SEC Compliance CEO stated, “Our goal is to reduce the ‘pain’ and inconvenience of filing. SEC Compliance provides affordable and effective services for financial reporting and distribution by applying innovative technologies to improve productivity. Providing TopiCanna samples captures this idea in a clever and hopefully memorable way.”
“TopiCanna is the flagship product in Tauriga’s new natural wellness product line, and we are pleased to showcase our proprietary cream to small cap and mid cap investors and other attendees at the B. Riley Conference,” said Dr. Stella M. Sung, Chief Executive Officer. “Although we are in different sectors, we share a big picture vision with SEC Compliance in that both companies strive to provide better and more cost effective alternatives by leveraging innovation and better managing resources, whether in natural medicine or in technical services.”
About SEC Compliance
SEC Compliance, Inc. (www.compliance-sec.com) has distinguished itself as a market leader of disclosure management solutions for publicly traded companies and others required by law to submit corporate information and financial statements electronically with the U.S. Securities and Exchange Commission.
From document EDGARization or XBRL Tagging to filing services and distribution, SEC Compliance provides qualified support and technical solutions that help companies streamline financial information while providing 30% cost-reductions guaranteed.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com and the Company’s e-commerce website at www.taurigastore.com.
NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.
CONTACT:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: +1-858-353-5749
Montreal: +1-514-840-3697
Email: ssung@tauriga.com
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/sec-compliance-featuring-products-from-tauriga-sciences-inc-at-b-riley–co-conference-300080734.html
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
